Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry
© 2018 Springer Science+Business Media, LLC, part of Springer Nature Purpose: The effectiveness of statins in improving clinical outcomes among patients with heart failure (HF) undergoing percutaneous coronary intervention (PCI) is unclear. We examined the association between use of statins and clin...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
2018
|
| Online Access: | http://hdl.handle.net/20.500.11937/65436 |
| _version_ | 1848761131759304704 |
|---|---|
| author | Chin, K. Wolfe, R. Reid, Christopher Tonkin, A. Hopper, I. Brennan, Angela Andrianopoulos, N. Duffy, S. Clark, D. Ajani, A. Liew, D. |
| author_facet | Chin, K. Wolfe, R. Reid, Christopher Tonkin, A. Hopper, I. Brennan, Angela Andrianopoulos, N. Duffy, S. Clark, D. Ajani, A. Liew, D. |
| author_sort | Chin, K. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | © 2018 Springer Science+Business Media, LLC, part of Springer Nature Purpose: The effectiveness of statins in improving clinical outcomes among patients with heart failure (HF) undergoing percutaneous coronary intervention (PCI) is unclear. We examined the association between use of statins and clinical outcomes in patients with HF included in the Melbourne Interventional Group registry. Methods: Patients were followed from 30 days to 1 year post-PCI for a primary composite outcome of all-cause mortality and hospitalisation for cardiovascular (CV) causes. Secondary outcomes included major adverse cardiac events (MACE, a composite of all-cause mortality, myocardial infarction and target vessel revascularisation) and hospitalisation for CV causes. Outcomes were compared between statin-treated and non-statin-treated patients (at 30 days post-PCI) using propensity scores to balance for risk factors. Results: Among 991 patients included in the inverse probability-weighted Cox model, statin use had no significant effect on the primary composite outcome [adjusted hazard ratio (aHR), 1.03; 95% confidence interval (CI), 0.68 to 1.56; p = 0.89] , nor MACE (aHR, 0.99; 95% CI, 0.54 to 1.84; p = 0.99) or hospitalisation for CV causes (HR, 1.13; 95% CI, 0.74 to 1.72; p = 0.57). Conclusions: Our results suggest that statin therapy may confer no significant benefits in patients with HF undergoing PCI. However, prospective randomised controlled trials are needed to provide more definitive answers. |
| first_indexed | 2025-11-14T10:26:48Z |
| format | Journal Article |
| id | curtin-20.500.11937-65436 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T10:26:48Z |
| publishDate | 2018 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-654362018-02-19T08:06:29Z Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry Chin, K. Wolfe, R. Reid, Christopher Tonkin, A. Hopper, I. Brennan, Angela Andrianopoulos, N. Duffy, S. Clark, D. Ajani, A. Liew, D. © 2018 Springer Science+Business Media, LLC, part of Springer Nature Purpose: The effectiveness of statins in improving clinical outcomes among patients with heart failure (HF) undergoing percutaneous coronary intervention (PCI) is unclear. We examined the association between use of statins and clinical outcomes in patients with HF included in the Melbourne Interventional Group registry. Methods: Patients were followed from 30 days to 1 year post-PCI for a primary composite outcome of all-cause mortality and hospitalisation for cardiovascular (CV) causes. Secondary outcomes included major adverse cardiac events (MACE, a composite of all-cause mortality, myocardial infarction and target vessel revascularisation) and hospitalisation for CV causes. Outcomes were compared between statin-treated and non-statin-treated patients (at 30 days post-PCI) using propensity scores to balance for risk factors. Results: Among 991 patients included in the inverse probability-weighted Cox model, statin use had no significant effect on the primary composite outcome [adjusted hazard ratio (aHR), 1.03; 95% confidence interval (CI), 0.68 to 1.56; p = 0.89] , nor MACE (aHR, 0.99; 95% CI, 0.54 to 1.84; p = 0.99) or hospitalisation for CV causes (HR, 1.13; 95% CI, 0.74 to 1.72; p = 0.57). Conclusions: Our results suggest that statin therapy may confer no significant benefits in patients with HF undergoing PCI. However, prospective randomised controlled trials are needed to provide more definitive answers. 2018 Journal Article http://hdl.handle.net/20.500.11937/65436 10.1007/s10557-018-6769-y restricted |
| spellingShingle | Chin, K. Wolfe, R. Reid, Christopher Tonkin, A. Hopper, I. Brennan, Angela Andrianopoulos, N. Duffy, S. Clark, D. Ajani, A. Liew, D. Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry |
| title | Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry |
| title_full | Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry |
| title_fullStr | Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry |
| title_full_unstemmed | Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry |
| title_short | Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry |
| title_sort | does statin benefits patients with heart failure undergoing percutaneous coronary intervention? findings from the melbourne interventional group registry |
| url | http://hdl.handle.net/20.500.11937/65436 |